Sectors

PODD
Insulet Corporation
151.49
1 x 138.46
1 x 162.83
bid
ask
+
2.81
1.89%
11:57 AM
timesize
Ytd -46.70%
1y -52.96%
149.90
day range
153.78
148.68
52 week range
352.82
Open 149.90 Prev Close 148.68 Low 149.90 High 153.78 Mkt Cap 10.48B
Vol 350.61K Avg Vol 1.22M EPS 4.28 P/E 35.34 Forward P/E 18.45
Beta 1.20 Short Ratio 2.82 Inst. Own 106.05% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 08-06 50-d Avg 199.82 200-d Avg 276.21 1yr Est 250.13
Earning
Date For Estimate Reported Surprise surprise %
2026-05-06 2026-03 1.14 1.42 0.28 24.56%
2026-02-18 2025-12 1.48 1.55 0.07 4.73%
2025-11-06 2025-09 1.13 1.24 0.11 9.73%
2025-08-07 2025-06 0.93 1.17 0.24 25.81%
2025-05-08 2025-03 0.81 1.02 0.21 25.93%
2025-02-20 2024-12 1.05 1.15 0.1 9.52%
Upgrade / Downgrade
Date Firm Action From To
2026-05-08 Barclays Upgrade Underweight Underweight
2026-05-07 Canaccord Genuity Upgrade Buy Buy
2026-05-07 JP Morgan Upgrade Overweight Overweight
2026-05-07 RBC Capital Upgrade Outperform Outperform
2026-05-07 Truist Securities Upgrade Buy Buy
2026-05-07 Evercore ISI Group Upgrade Outperform Outperform
Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Insider Holder
Date Name Relation Quantity Description
2026-02-23 BENJAMIN ERIC Chief Operating Officer 24.51K Stock Award(Grant)
2025-02-24 CHADWICK ANA MARIA Chief Financial Officer 16.03K Stock Award(Grant)
2025-02-24 FIELD MARK N Chief Technology Officer 13.92K Stock Award(Grant)
2025-02-24 HOLLINGSHEAD JAMES R Chief Executive Officer 68.07K Stock Award(Grant)
2025-05-21 HOPFIELD JESSICA Director 27.70K Stock Award(Grant)
2026-02-23 KAPPLES JOHN W. General Counsel 28.12K Stock Award(Grant)
Institution Ownership
Report Date Organization Position Value Percentage
2026-03-30 Blackrock Inc. 6.38M 947.98M 9.21%
2025-12-30 FMR, LLC 6.33M 940.45M 9.13%
2026-03-30 Vanguard Capital Management LLC 4.58M 680.85M 6.61%
2026-03-30 Vanguard Portfolio Management LLC 3.45M 512.94M 4.98%
2025-12-30 State Street Corporation 3.16M 469.16M 4.56%
2026-03-30 BAILLIE GIFFORD & CO 2.03M 301.74M 2.93%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 2.22M 329.80M 3.20%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard 500 Index Fund 1.77M 263.74M 2.56%
2026-03-30 iShares Trust-iShares Core S&P 500 ETF 904.23K 134.44M 1.31%
2026-03-30 AMCAP FUND 900.00K 133.81M 1.30%
2026-03-30 Fidelity Concord Street Trust-Fidelity 500 Index Fund 898.39K 133.57M 1.30%
2026-03-30 Fidelity Securities Fund-Fidelity OTC Portfolio 889.38K 132.23M 1.28%